President Trump and Chief of Staff Mark Meadows (Sarah Silbiger/UPI/Bloomberg via Getty Images)

Fac­ing broad push­back from in­dus­try, White House backs down on FDA's Covid-19 vac­cine guid­ance

Fac­ing thin­ly-veiled crit­i­cism from the na­tion’s largest drug­mak­ing lob­by and a di­rect refu­ta­tion from the CEO of the lead­ing Covid-19 vac­cine de­vel­op­er, the White House has backed off of its ef­forts to block FDA guid­ance that would place stricter re­quire­ments for a coro­n­avirus vac­cine to win au­tho­riza­tion, sev­er­al out­lets re­port­ed.

The move like­ly means that Pfiz­er’s vac­cine will not meet the FDA’s stan­dards be­fore Elec­tion Day, as Pres­i­dent Don­ald Trump has re­peat­ed­ly promised over the ob­jec­tion of his own pub­lic health of­fi­cials and in­de­pen­dent ex­perts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.